The role of neuroinflammation on pathogenesis of affective disorders

Sung Ja Rhie1,†, Eun-Yee Jung2,†, Insop Shim2,*

1Department of Beauty and Health, Halla University, Wonju, Korea
2Department of Physiology, College of Medicine, Kyung Hee University, Seoul, Korea

Accumulating evidence suggests that neuroinflammation plays an important role in etiology of psychiatric disorders. Neuroinflammation involves a combination of psychological, neuroendocrine, and nervous systems resulting in changes of neurotransmitter metabolism, dysregulation of the hypothalamus-pituitary-adrenal axis, pathologic microglial cell activation, impaired neuroplasticity, and structural and functional brain changes affecting cognition and emotional behavior. Inflammatory cytokines have been postulated to be the possible link and culprit in the disruption of these systems. The outcome of any type of dysregulation of the immune system in the brain might lead to occurrence of depression, anxiety. This review focuses on the possible impact of dysregulated cytokine networks which may cause pathogenesis of affective disorders such as depression and anxiety.

Keywords: Neuroinflammation, Cytokines, Depression, Affective disorders

INTRODUCTION

The term of “psychoneuroimmunology” was introduced in 1960s in order to define the bidirectional relationship between brain and immune system (Straub and Cutolo, 2018). In this respect, there have been increasing interests in the possible involvement of the immune system in psychiatric disorders. Moreover, changes in the immune system can lead to profound alterations in psychological state such as mood and behavior. The most possible link interacting behavior, nervous, endocrine and immune systems are established by the cytokines which act as signaling molecules of the immune system. Several studies indicated a close association between activation of pro-inflammatory cytokines including interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ) and psychiatric symptoms (Anisman et al., 2005; Arisi, 2014; Konsman et al., 2002; Levine et al., 1999). During systemic infections, cancer or autoimmune diseases, pro-inflammatory cytokines can induce behavioral symptoms referred to as sickness behavior which is accompanied by a feeling of helplessness, depression, anxiety, excessive sleep, decreased appetite, and decreased concentration (Dantzer, 2001). These studies suggest that cytokines play an important role in the mood disorder and behavioral dysfunction.

In the clinical study, the increase in plasma concentrations of the pro-inflammatory cytokines observed in patients suffering from depression is known to be closely correlated with the severity of this psychiatric disorder, the hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and the deficiency in serotonergic (5-HT) neurotransmission (Kim et al., 2002; Maes et al., 1993; Maes et al., 1995; Maes et al., 1997; Maes et al., 1999; Nunes et al., 2002). Several medical conditions e.g., autoimmune disease such as rheumatoid arthritis, cancer, or hepatitis C therapies producing activation of the immune system are associated with psychological and neuroendocrine changes that resemble the characteristics of depression including depressed mood, appetite disturbance, sleep disturbance, psycho motor disturbance, fatigue, loss
of energy, difficulty in thinking or concentrating, activation of the immune system, hyperactivity of HPA axis, and monoaminergic alterations (Bonaccorso et al., 2000; Rogler and Andus, 1998; Van Gool et al., 1999; Weinblatt et al., 1999). Similarly, systemic administration of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α in animals induces increase HPA activity (Dantzer, 2001; Dorr, 1993; Yirmiya, 2000; Yirmiya et al., 2000). Recently, evidence supports a role of cytokines, especially IL-1, IL-6, TNF-α, and IFN-γ in the pathophysiology of depression and anxiety (Dorr, 1993; Guo et al., 2014). This could be due to the actions of pro-inflammatory cytokines as signaling molecules on neurotransmitter metabolism and neurocircuitry in the brain. This review focuses on the possible influences of neuroinflammation which may cause pathogenesis of affective disorders including depression and anxiety (Fig. 1).

**CYTOKINES**

Cytokines are signaling molecules released from the periphery immune cells (monocytes, macrophages, and lymphocytes). They act as intercellular messengers and are associated with activation of the immune system, cell differentiation, and cell death (Allan and Rothwell, 2003; Salim et al., 2012). Cytokines can be divided into pro-inflammatory cytokines such as IL-1β, IL-6, IFN-γ, and TNF-α which activate inflammation. In contrast, anti-inflammatory cytokines such as interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-13 (IL-13) inhibit inflammation (Abbas et al., 1996). Cytokines interact with each other to keep the balance between pro-inflammatory and anti-inflammatory cytokines. Systemic injection of pro-inflammatory cytokines induces depression-like behaviors (Dantzer et al., 2001), whereas treatment of antidepressants in depression attenuates cytokine production and their action (Barden, 1999; Castanon et al., 2002; Schiepers et al., 2005). Pro-inflammatory cytokines produced from the peripheral immune system are delivered directly to the central nervous system or indirectly affect the brain by increasing nitric oxide (NO), prostaglandins (PGE2) (Capuron and Miller, 2011). Cytokines are also produced by neurons and glial cells (microglia, astrocytes, and oligodendrocytes) of the brain and can cause or reflect abnormalities in the central nervous system (Becher et al., 2017).

**NEUROINFLAMMATION**

Peripheral cytokines are hydrophilic and because of their relatively high weight they cannot pass through blood-brain barrier (BBB) under normal conditions. However, in pathological conditions with increased BBB permeability, peripheral cytokines can pass through the BBB (Lacroix and Rivest, 1998; Wong et al., 1996). Also, peripherally produced cytokines can cross the circumventricular organs and the choroid plexus where relatively leaky
regions of the BBB (Quan and Banks, 2007). Another mechanism is the binding of cytokines to peripheral afferent nerve fibers in the vagus nerve then relay cytokine signals to relevant brain regions through activation of the nucleus of the tractus solitarius and area postrema (Capuron and Miller, 2011; Miller et al., 2009). In then, transmission of these cytokine signals occurs through secondary mediators, PGE2, that elicit physiological and behavioral responses. Peripherally activated cytokines are actively transported into the brain-stimulating microglial and astrocytes cells, which in turn produce cytokines (Müller and Ackenheil, 1998). Microglia which is the principal cellular mediators of inflammatory processes in the brain (Graeber, 2010; Wake et al., 2009) can produce pro-inflammatory cytokines, NO, and reactive oxygen species (Harry and Kraft, 2008).

Furthermore, increased microglia by peripheral inflammation recruits monocytes into the brain and the cerebral infiltrated monocytes can further produce pro-inflammatory cytokines (D’Mello et al., 2009; Peraçoli et al., 2003). Postmortem and positron emission tomography (PET) imaging studies identified microglia activation in individuals who committed suicide (Schnieder et al., 2014; Steiner et al., 2008; Torres-Platas et al., 2014). Such increases in pro-inflammatory cytokines may influence the brain by increasing neurotoxic metabolites, or directly exerting neurotoxic effects on specific brain regions implicated in regulation of emotional response, including the amygdala, hippocampus, hypothalamus, and the cerebral cortex (Shim et al., 2019). Moreover, cytokine signaling in the brain is known to regulate important brain functions including neurotransmitter metabolism, neuroendocrine function, and mood-regulating neurocircuity. The outcome of any type of dysregulation of the immune system in the brain might lead to occurrence of depression and anxiety (Salim et al., 2012). Inflammatory cytokines such as TNF-α and IL-1β may also activate microglia, reducing neuroplasticity and consequently depressing the function of neuronal circuits which is involved in mood regulation (Miller and Raison, 2016). Increased IL-1β activates astrocytes (Caž et al., 2006) and some studies reveal an influence of different classes of antidepressant medications on astrocytes (Banasz et al., 2010; Rajkowska and Stockmeier, 2013; Wang et al., 2014). Astrocytes regulate synaptic and intracellular levels of neurotransmitters including glutamate and γ-aminobutyric acid (GABA) via transporters located on their processes (Lee et al., 2011; Sattler and Rothstein, 2006; Sofroniew and Vinters, 2010). In laboratory animal study, hypothalamic astrocytes activation following IL-1β infusion induced anxiety symptoms and hypothalamic astrocytes inhibition reduced anxiety behaviors which were relevant with astrocytic GABA release (Shim et al., 2019).

**EFFECTS OF NEUROINFLAMMATION ON NEUROTTRANSMITTERS**

Pro-inflammatory cytokines including IL-1β, IFN, and TNF can reduce the bioavailability of neurotransmitters such as serotonin (5-HT), norepinephrine (NE), dopamine (DA) and excitatory amino acid glutamate (Miller and Timmie, 2009). Increased pro-inflammatory cytokines may reduce 5-HT availability in the synapse by activating of indolamine 2,3 dioxygenase (IDO), the enzyme to metabolize tryptophan which is the primary amino acid precursor of 5-HT, into kynurenine resulting in decreased 5-HT synthesis (Capuron et al., 2002; Capuron et al., 2003). In addition, activation of p38 mitogen-activated protein kinase can upregulate the expression and activity of the membrane transporter for 5-HT, NE, and DA (Miller and Timmie, 2009). Cytokine-induced activation of NO can lead to decreased tetrahydrobiopterin which serves as a coenzyme for tyrosine hydroxylase, the rate-limiting enzyme in DA synthesis in leading to decreased DA as well as NE availability. Several studies have documented that activation of IDO in the brain plays a critical role in the development of depressive-like behavior in rodents (Lestage et al., 2002; O’Connor et al., 2009). Moreover, increases in kynurenine and decreases in tryptophan levels have been associated with the depression and severity of depressive symptoms in humans (Capuron et al., 2003). Activated microglia can convert kynurenine into quinolinic acid (QUIN), which is a potent N-methyl-d-aspartate (NMDA) receptor agonist, a glutamate receptor, and together with cytokine-induced reduction in astrocytic glutamate reuptake and stimulation of astrocyte glutamate release, which in turn can lead to excessive glutamate. Excessive glutamate, especially when binding to extra synaptic NMDA receptor, can, in turn, lead to decreased brain-derived neurotrophic factor (BDNF) and excite toxicity leading to depression (Harry and Kraft, 2012; Hashimoto et al., 2013).

**EFFECTS OF NEUROINFLAMMATION ON NEUROCIRCUITY**

To study microglial activation in depression in vivo, PET imaging studies using various PET ligands for the microglial marker translocator protein have been conducted. In human postmortem studies, Depression associated microglial activation is particularly observed in the prefrontal cortex, insula, and anterior cingulate cortex (ACC) have been correlated with the severity and duration...
of depression (Schnieder et al., 2014; Setiawan et al., 2018; Stein-
er et al., 2008). In addition, suicide has been related not only to mi-
roglial activation, but also to an enhanced perivascular macro-
phage around blood vessels (Torres-Platas et al., 2014). Inflam-
mentation can affect growth factors such as BDNF in the dentate gyrus
of the hippocampus, and also affect fundamental aspects of neural
integrity including neurogenesis, long-term potentiation, and
dendritic sprouting, ultimately affecting learning and memory.
Cytokine may influence neurotransmitter systems, especially DA,
resulting in inhibiting several aspects of reward motivation and
anhedonia in corticostriatal circuits involving the basal ganglia,
ventromedial prefrontal cortex and subgenual and dorsal ACC
(sgACC and dACC, respectively), while also activating circuits regu-
ulating anxiety, arousal, and fear including the amygdala, hip-
pocampus, dACC, and insula (Miller and Raison, 2016). In line
with the influence of cytokones on NE release, cytokones and im-
mune activation increase activity of locus coeruleus (LC) which is
the principal site of NE synthesis in the brain and NE projects to
the hippocampus and hypothalamus. This increase in NE activity
induces HPA-axis activation, fever, and metabolic change associ-
ated with immune activation (Dunn et al., 1999; Dunn et al.,
2005). However, chronically prolonged stress-induced decline of
IL-4 concentration and NE activity in LC indicates glucocorticoid
negative feedback leading to HPA-axis hyperactivity which is
anxiety-like behavior and an inverse relationship exists between
IL-4 secretion and HPA/sympathetic-adrenal-medullary axes acti-
vation (Lee et al., 2016).

PATHOGENESIS OF NEUROINFLAMMATION IN PSYCHIATRIC DISORDERS

Stress has been associated to the development of both depres-
sion and anxiety, with a key contribution of microglia activation,
as well as of recruitment of peripheral macrophages into the brain.
On the other hand, the neuroinflammatory status associated with
depression-like symptoms may also result from the existence of
peripheral or central chronic inflammatory processes that continu-
ously activate peripheral macrophages, sending inflammatory sig-
nals to the brain resulting in monoamine depletion, down-regula-
tion of neuropeptide signaling, and glucocorticoid receptor resis-
tance, as well as excess of glutamate, corticotrophin-releasing hor-
mones and glucocorticoid levels (Jo et al., 2015; Roman et al.,
2013). Acute psychosocial stress can induce both anti-inflammatory
and pro-inflammatory responses. Cells of the immune system are nor-
mally sensitive to increases in glucocorticoids induced by stress-
ors. Glucocorticoids regulate both immune functions and HPA
axis through binding to glucocorticoid receptors. Once activated,
the glucocorticoids receptor translocates into the nucleus and up-
regulate expression of anti-inflammatory cytokine such as IL-10
and represses inflammatory signaling pathways, including inhib-
iting nuclear factor-kappa B (NF-kB), a major transcription factor
for pro-inflammatory cytokines. During acute stress, the increased
GR sensitivity leads to better control of inflammation. However,
chronic glucocorticoids levels are observed low during chronic
stress and depression. In this case, steroid resistance (e.g., lower
GR numbers or reduced affinity) occurs, leading to increased in-
flammation by activating NF-kB and its target genes coding for
pro-inflammatory mediators. Depression is often associated pro-
longed with HPA-axis hyperactivity, cytokine-induced activation
of IDO may also be involved in the attenuation of negative feed-
back inhibition of circulating glucocorticoids on the HPA axis,
through production of the kynurenine metabolite QUIN. QUIN
is hypothesized to cause hippocampal atrophy and loss of gluco-
corticoids receptor (Wichers and Maes, 2004). Also, inflammatory
cytokines can activate the HPA axis, inhibit the inhibitory feed-
back loop, increase cortisol, and reduce neuroplasticity, causing
depression (Sigalas et al., 2012).

POTENTIAL TREATMENT ASSOCIATED WITH THE REGULATION OF
NEUROINFLAMMATION

If neuroinflammation is involved in etiology of depression and
anxiety, it can be assumed that antineuroinflammation drugs
might have an effect on depression and anxiety. Some patients
with depression respond to antidepressant treatment, but about
30% show either no improvement or only partial responses ac-
companied by side effects (Al-Harbi, 2012). In addition to con-
ventional anti-inflammatory drugs, theoretically, pro-inflammatory
cytokine receptor inhibitors, pro-inflammatory cytokine antago-
nists, and anti-inflammatory cytokines can be applied to the treat-
ment of depression and anxiety. Actually, TNF-α antagonists, and
anti-inflammatory agents such as omega 3 and curcumin can act
as an antidepressant. Among the nonsteroidal anti-inflammatory
drugs, aspirin (acetyl-salicylic acid), known as an irreversible in-
hibitor of cyclooxygenase (COX)-1 and COX-2, has been shown
to have antidepressant effects when used in combination with
conventional antidepressant treatments in several clinical studies
(Berk et al., 2013). In addition, celecoxib, a COX-2 selective in-
hibitor, has been shown to have antidepressant effects when used

https://doi.org/10.12965/jer.2040016.008
in combination with conventional antidepressants in several clinical studies in patients with depression (Faridhosseini et al., 2014). Celecoxib was able to reduce the pro-inflammatory cytokines such as IL-1β and TNF-α in rat hippocampus and this inhibition was shown to prevent clinical symptoms such as anxiety and cognitive impairments (Casolini et al., 2002). Among the TNF-α antagonists, infliximab is currently used as a treatment for autoimmune diseases, but is also receiving attention as a treatment for treatment-resistant depression (Ekdahl, 2012). In a randomized controlled study to determine the antidepressant effect of infliximab intravenously in patients with treatment-resistant depression, infliximab (5 mg/kg) did not show any significant difference between the drug and antidepressant effects. In the group with high value (above 5 mg/dL), antidepressant effect was confirmed (Raison et al., 2013). In animal study, chronic and systemic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behavior in rat model of chronic mild stress (Karnon et al., 2013). Culinmin is also a natural product with strong anti-inflammatory and antioxidant effects (See et al., 2015). Doxycycline and minocycline, which belong to the tetracycline family of antibiotics, also have strong anti-inflammatory effects, which may have antidepressant effects (Levine et al., 1996).

CONCLUSIONS

Depression and anxiety have many similarities with the sickness behavior and symptoms in inflammatory conditions, and the use of cytokines for the treatment of cancer or hepatitis C therapies increases the incidence of depression, highlighting the link between inflammation and depression. Higher levels of inflammatory mediators have been linked with the etiology and clinical progression of neuropsychiatric disorders. Of note, neuroinflammation involves a combination of psychological and neuroendocrine and nervous systems, resulting in changes of neurotransmitter metabolism, dysregulation of the HPA axis, pathologic microglial cell activation, impaired neuroplasticity, and structural and functional brain changes. Until now, it is imperative to identify specific molecular targets of regulation of neuroinflammation that may be critical for novel immune-based therapeutics for mental health disorders. Future research should also examine the effects of antidepressants on immune function and cytokine secretion, as well as the clinical effects of cytokine inhibitors and cytokine antagonists on the psychological and pathophysiological features of depression. Gaining a better understanding of the role of neuroinflammatory mechanisms and regulator of neuroinflammation may offer new insights for novel therapeutic options for psychiatric disorders.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

This work was supported by grants from the National Research Foundation of the Korean government (NRF-2016M3C7A1905384).

REFERENCES

Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012;6:369-388.
Allan SM, Rothwell NJ. Inflammation in central nervous system injury. Philos Trans R Soc Lond B Biol Sci 2003;358:1669-1677.
Anisman H, Merali Z, Poulter MO, Hayley S. Cytokines as a precipitant of depressive illness: animal and human studies. Curr Pharm Des 2005;11:963-972.
Arisi GM. Nervous and immune systems signals and connections: cytokines in hippocampus physiology and pathology. Epilepsy Behav 2014;38:43-47.
Banasr M, Chowdhury GM, Tervoilliger R, Newton SS, Duman RS, Behar KL, Sanacora G. Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Mol Psychiatry 2010;15:501-511.
Barden N. Regulation of corticosteroid receptor gene expression in depression and antidepressant action. J Psychiatry Neurosci 1999;24:25-39.
Becher B, Spath S, Goverman J. Cytokine networks in neuroinflammation. Nat Rev Immunol 2017;17:49-59.
Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, Davey CG, Sanna L, Maes M. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 2013;11:74.
Bonaccorso S, Meltzer H, Maes M. Psychological and behavioural effects of interferon-α. Curr Opin Psychiatry 2000;13:673-677.
Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011;130:226-238.
Capuron L, Neurauter G, Musselman DL, Lawson DH, Nemeroff CB, Fuchs D, Miller AH. Interferon-α-induced changes in tryptophan me-
tabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-914.

Capuron L, Ravaud A, Neveu PJ, Miller AH, Maes M, Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 2002;7:468-473.

Casolini P, Catalani A, Zuena AR, Angelucci L. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002;68:337-343.

Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antidepressants on cytokine production and actions. Brain Behav Immun 2002;16:569-574.

Czéh B, Simon M, Schmelting B, Hiemke C, Fuchs E. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006;31:1616-1626.

Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001;933:222-234.

D’Mello C, Le T, Swain MG. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009;29:2089-2102.

Dorr RT. Interferon-α in malignant and viral diseases. A review. Drugs 1993;45:177-211.

Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 2005;29:891-909.

Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999;461:117-127.

Ekdhålt CT. Microglial activation - tuning and pruning adult neurogenesis. Front Pharmacol 2012;3:41.

Faridhosseini F,Sadeghi R, Farid L, Pourgholami M. Celecoxib: a new augmentation strategy for depressive mood episodes. A systematic review and meta-analysis of randomized placebo-controlled trials. Hum Psychopharmacol 2014;29:216-223.

Graeber MB. Changing face of microglia. Science 2010;330:783-788.

Guo J, Lin P, Zhao X, Zhang J, Wei X, Wang Q, Wang C. Etazolate abrogates the lipopolysaccharide (LPS)-induced downregulation of the cAMP/pCREB/BDNF signaling, neuroinflammatory response and depressive-like behavior in mice. Neuroscience 2014;263:1-14.

Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 2012;33:191-206.

Harry GJ, Kraft AD. Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment. Expert Opin Drug Metab Toxicol 2008;4:1265-1277.

Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013;263:367-377.

Karson A, Demirtaş T, Bayramgürler D, Balci F, Utkan T. Chronic administration of infliximab (TNF-α inhibitor) decreases depression and anxiety-like behaviour in rat model of chronic mild stress. Basic Clin Pharmacol Toxicol 2013;112:335-340.

Kim YK, Suh IB, Kim H, Han CS, Lim CS, Choi SH, Licinio J. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol Psychiatry 2002;7:1107-1114.

Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154-159.

Lacroix S, Rивest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cylooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 1998;70:452-466.

Lee HJ, Park HJ, Starkweather A, An K, Shim I. Decreased interleukin-4 release from the neurons of the locus coeruleus in response to immobilization stress. Mediators Inflamm 2016;2016:3501905.

Lee M, Schwab C, McGeer PL. Astrocytes are GABAergic cells that modulate microglial activity. Glia 2011;59:152-165.

Lestage J, Verrier D, Palin K, Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 2002;16:596-601.

Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999;40:171-176.

Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline. Am J Psychiatry 1996;153:582.

Maes M, Bosmans E, De Jongh R, Kenis G, Vandoollaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997;9:853-858.

Maes M, Bosmans E, Meltzer HY, Scharpé S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am J Psychiatry 1993;150:1189-1193.

Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoollaeghe E, Ranjan R, Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 1995;34:301-309.

Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpé S. Negative immunoregulatory effects of antidepressants: in-
hibition of interferon-γ and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999;20:370-379.

Miller AH, Maletic V, Raison CL. Inflammation and its contents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009;65:732-741.

Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2016;16:22-34.

Miller AH, Timmie WP. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the Translational Interface Norman Cousins Lecture. Brain Behav Immun 2009;23:149-158.

Müller N, Ackenheil M. Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 1998;22:1-33.

Nunes SO, Reiche EM, Morimoto HK, Matsuo T, Itano EN, Xavier EC, Yamashita CM, Vieira VR, Menoli AV, Silva SS, Costa FB, Reiche FV, Silva FL, Kaminami MS. Immune and hormonal activity in adults suffering from depression. Braz J Med Biol Res 2002;35:581-587.

O’Connor JC, André C, Wang Y, Lawson MA, Szegedi SS, Lestado J, Castanon N, Kelley KW, Dantzer R. Interferon-γ and tumor necrosis factor-α mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci 2009;29:4200-4209.

Peraçoli MT, Kurokawa CS, Calvi SA, Mendes RP, Pereira PC, Marques SA, Soares AM. Production of pro- and anti-inflammatory cytokines by monocytes from patients with paracoccidioidomycosis. Microbes Infect 2003;5:413-418.

Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun 2007;21:727-735.

Rajkowska G, Stockmeier CA. Astrocyte pathology in major depressive disorder: insights from human postmortem brain tissue. Curr Drug Targets 2013;14:1225-1236.

Raison CL, Raftery RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013; 70:31-41.

Rogler G, Andrus T. Cytokines in inflammatory bowel disease. World J Surg 1998;22:382-389.

Salim S, Chugh G, Asghar M. Inflammation in anxiety. Adv Protein Chem Struct Biol 2012;88:1-25.

Sattler R, Rothstein JD. Regulation and dysregulation of glutamate transporters. Handb Exp Pharmacol 2006(175):277-303.

Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:201-217.
Neurosci 2004;29:11-17.
Wong ML, Rettori V, al-Shokhlee A, Bongiorno PB, Canteros G, McCann SM, Gold PW, Licinio J. Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nat Med 1996;2:581-584.

Yirmiya R. Depression in medical illness: the role of the immune system. West J Med 2000;173:333-336.
Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, Shavit Y, Ovadia H, Weidenfeld J, Morag A, Newman ME, Pollmächer T. Illness, cytokines, and depression. Ann N Y Acad Sci 2000;917:478-487.